ImmunoPDT

ImmunoPDT is a next-generation biotech company revolutionizing the treatment of prostate cancer through a safe, effective, and immune-activating therapy. Built on more than a decade of research, $50 million of development, and world-class partnerships, our team has pioneered Immuno-Photodynamic Therapy (ImmunoPDT) — a harmless, plant-derived treatment that targets cancer cells without damaging healthy tissue.

We are led by internationally recognized clinicians, scientists, and innovators with decades of combined experience in urology, oncology, pharmaceuticals, and medical research. Together, we are driving a paradigm shift in prostate cancer care — where long-term survival, safety, and quality of life come first.